Company Overview of Targacept, Inc.
As of August 20, 2015, Targacept, Inc. was acquired by Catalyst Biosciences, Inc. Targacept, Inc., a biopharmaceutical company, engages in the development of neuronal nicotinic receptors (NNR) therapeutics for the treatment of nervous system and gastrointestinal/genitourinary diseases and disorders. Its product candidates include TC-6499 for the treatment of diabetic gastroparesis; and TC-5619 and TC-6987, which are novel small molecules that are selective for the a7 NNR. The company was founded in 1997 and is based in Winston-Salem, North Carolina.
100 North Main Street
Winston-Salem, NC 27101
Founded in 1997
Key Executives for Targacept, Inc.
Targacept, Inc. does not have any Key Executives recorded.
Targacept, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
To contact Targacept, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.